<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03239496</url>
  </required_header>
  <id_info>
    <org_study_id>IPV004</org_study_id>
    <nct_id>NCT03239496</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV</brief_title>
  <official_title>A Phase 3, Open-label, Multicenter Randomized Trial to Evaluate Humoral Immunogenicity of Various Schedules of Intramuscular Full-Dose and Intradermal Fractional Dose of Inactivated Polio Vaccine in Latin American Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fidec Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fidec Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess and compare the immune response to full-dose inactivated polio vaccines&#xD;
      (IPV) via intramuscular (IM) administration and of the fractional dose of inactivated&#xD;
      poliovirus vaccine (f-IPV) via intradermal (ID) administration, in different schedule&#xD;
      combinations in the Expanded Program on Immunization (EPI) primary series.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study prioritizes comparisons involving two-dose regimens recently recommended by the&#xD;
      World Health Organization (WHO) Strategic Advisory Group of Experts on immunization (SAGE)&#xD;
      and Pan American Health Organization (PAHO) in response to global IPV supply shortages 21.&#xD;
      Furthermore, the study will provide data on the comparative humoral immunogenicity of various&#xD;
      schedules to inform polio immunization policy for the post-eradication era.&#xD;
&#xD;
      The study population will include infants in Dominican Republic and Panama. Absence of wild&#xD;
      and circulating vaccine derived polioviruses along with the lack of regular Supplementary&#xD;
      Immunization Activities (SIAs) in the Latin America region provide an ideal epidemiologic&#xD;
      setting to study polio vaccine immunogenicity.&#xD;
&#xD;
      Infants will receive two or three doses of full-dose IPV IM or f-IPV ID, in two schedules&#xD;
      (10, 14 and 36 weeks and 14 and 36 weeks). Immunological and safety assessments will be made&#xD;
      after one dose, two doses and three doses.&#xD;
&#xD;
      A total of 773 infants will be enrolled and distributed into 4 groups, according to a&#xD;
      randomization scheme. During the study period, infants will be administered other concomitant&#xD;
      vaccines according to the national schedules of the participating countries, but the effect,&#xD;
      if any, of the concomitant administration on IPV immunogenicity will not be assessed.&#xD;
&#xD;
      Optimum immunogenicity expected from the dose(s) of IPV in the post-eradication era will have&#xD;
      to be balanced with the cost and supply constraints of IPV. This study will be critical to&#xD;
      determine how many doses of IPV and which schedule are optimal for the post-eradication era&#xD;
      after the global cessation of Oral Polio Vaccine (OPV) use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Actual">November 13, 2018</completion_date>
  <primary_completion_date type="Actual">November 13, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion Non-inferiority of 2 Doses f-IPV ID vs 2 Doses IPV IM</measure>
    <time_frame>To be assessed 4 weeks after the last dose</time_frame>
    <description>To determine if the seroconversion rate of a 2-dose intradermally administered fractional-dose inactivated poliovirus vaccine (f-IPV) regimen administered at 14 and 36 weeks of age is non-inferior to that of a 2-dose intramuscularly administered inactivated poliovirus vaccine (IPV) regimen administered at 14 and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Non-inferiority of 2 Doses IPV IM vs 3 Doses IPV IM</measure>
    <time_frame>To be assessed 4 weeks after the last dose</time_frame>
    <description>To determine if the seroconversion rate of a 2-dose IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Non-inferiority of 2 Doses f-IPV ID vs 3 Doses f-IPV ID</measure>
    <time_frame>To be assessed 4 weeks after the last dose</time_frame>
    <description>To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose f-IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Superiority of 2 Doses IPV IM at Different Schedules</measure>
    <time_frame>To be assessed 4 weeks after the second dose</time_frame>
    <description>To determine if the seroconversion rate of a 2-dose IPV regimen administered at 14 and 36 weeks of age is superior to that of a 2-dose IPV regimen administered at 10 and 14 weeks of age for poliovirus serotypes 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Superiority of 2 Dose f-IPV ID at Different Schedules</measure>
    <time_frame>To be assessed 4 weeks after the second dose</time_frame>
    <description>To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is superior to that of a 2-dose f-IPV regimen administered at 10 and 14 weeks of age for poliovirus serotypes 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Non-inferiority of 2 Dose f-IPV ID vs 3 Dose IPV IM</measure>
    <time_frame>To be assessed 4 weeks after the last dose</time_frame>
    <description>To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Non Inferiority of 3 Doses f-IPV ID vs 3 Doses IPV IM</measure>
    <time_frame>To be assessed 4 weeks after the last dose</time_frame>
    <description>To determine if the seroconversion rate of a 3-dose f-IPV regimen administered at 10, 14, and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen also administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Non Inferiority of 3 Doses f-IPV ID vs 2 Doses IPV IM</measure>
    <time_frame>To be assessed 4 weeks after the last dose</time_frame>
    <description>To determine if the seroconversion rate to a 3-dose regimen of f-IPV administered at 10, 14, and 36 weeks of age is non-inferior to that of a 2-dose IPV regimen administered at 14 and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing SAEs, IMEs and/or Severe Local Reactions</measure>
    <time_frame>To be assessed throughout the complete study period, approx. 13 months</time_frame>
    <description>To assess the safety of each vaccine (IPV and f-IPV) as measured by the number of subjects experiencing serious adverse events (SAEs), important medical events (IMEs) and/or severe local reactions.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">773</enrollment>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses IPV IM at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses IPV IM at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses f-IPV ID at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses f-IPV ID at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IPV</intervention_name>
    <description>Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>f-IPV</intervention_name>
    <description>Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Infants of 6 weeks of age (-7 to + 7 days) on date of enrollment.&#xD;
&#xD;
          2. Healthy, as assessed from medical history and physical examination by a study&#xD;
             physician,&#xD;
&#xD;
          3. Written informed consent obtained from parents or legal representatives who have been&#xD;
             properly informed about the study and are able to comply with planned study&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Vaccinated with any poliovirus vaccine prior to inclusion,&#xD;
&#xD;
          2. A household contact with OPV vaccination history in the past 4 weeks,&#xD;
&#xD;
          3. HIV infection or pharmacologic immunosuppression,&#xD;
&#xD;
          4. Known allergy to any component of the study vaccines (phenoxyethanol, formaldehyde),&#xD;
&#xD;
          5. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular and&#xD;
             intradermal injections,&#xD;
&#xD;
          6. Acute severe febrile illness on day of vaccination deemed by the Investigator(s) to be&#xD;
             a contraindication for vaccination,&#xD;
&#xD;
          7. Not suitable for inclusion or is unlikely to comply with the protocol in the opinion&#xD;
             of the investigator(s).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Weeks</minimum_age>
    <maximum_age>7 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Se√±ora de la Alta Gracia</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cevaxin Vaccination Center</name>
      <address>
        <city>David</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cevaxin Vaccination Center</name>
      <address>
        <city>La Chorrera</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cevaxin Vaccination Center</name>
      <address>
        <city>Panama city</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>Panama</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 28, 2017</study_first_submitted>
  <study_first_submitted_qc>August 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2017</study_first_posted>
  <results_first_submitted>August 1, 2020</results_first_submitted>
  <results_first_submitted_qc>August 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2020</results_first_posted>
  <last_update_submitted>August 1, 2020</last_update_submitted>
  <last_update_submitted_qc>August 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT03239496/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>3 doses IPV IM at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>2 doses IPV IM at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
        </group>
        <group group_id="P3">
          <title>Group C</title>
          <description>3 doses f-IPV ID at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
        </group>
        <group group_id="P4">
          <title>Group D</title>
          <description>2 doses f-IPV ID at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="178"/>
                <participants group_id="P3" count="178"/>
                <participants group_id="P4" count="217"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="186"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="166"/>
                <participants group_id="P4" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>3 doses IPV IM at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>2 doses IPV IM at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>3 doses f-IPV ID at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
        </group>
        <group group_id="B4">
          <title>Group D</title>
          <description>2 doses f-IPV ID at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
            <count group_id="B2" value="178"/>
            <count group_id="B3" value="178"/>
            <count group_id="B4" value="217"/>
            <count group_id="B5" value="773"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="178"/>
                    <measurement group_id="B4" value="217"/>
                    <measurement group_id="B5" value="773"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="105"/>
                    <measurement group_id="B5" value="372"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="112"/>
                    <measurement group_id="B5" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="132"/>
                    <measurement group_id="B5" value="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latin American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White / Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Panama</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="100"/>
                    <measurement group_id="B5" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominican Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Non-inferiority of 2 Doses f-IPV ID vs 2 Doses IPV IM</title>
        <description>To determine if the seroconversion rate of a 2-dose intradermally administered fractional-dose inactivated poliovirus vaccine (f-IPV) regimen administered at 14 and 36 weeks of age is non-inferior to that of a 2-dose intramuscularly administered inactivated poliovirus vaccine (IPV) regimen administered at 14 and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
        <time_frame>To be assessed 4 weeks after the last dose</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group B</title>
            <description>2 doses IPV IM at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
          <group group_id="O2">
            <title>Group D</title>
            <description>2 doses f-IPV ID at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Non-inferiority of 2 Doses f-IPV ID vs 2 Doses IPV IM</title>
          <description>To determine if the seroconversion rate of a 2-dose intradermally administered fractional-dose inactivated poliovirus vaccine (f-IPV) regimen administered at 14 and 36 weeks of age is non-inferior to that of a 2-dose intramuscularly administered inactivated poliovirus vaccine (IPV) regimen administered at 14 and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
          <population>Per Protocol Population</population>
          <units>percentage of seroconversion</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="94.6" upper_limit="99.6"/>
                    <measurement group_id="O2" value="95.9" lower_limit="92.1" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="95.5" upper_limit="99.8"/>
                    <measurement group_id="O2" value="97.9" lower_limit="94.8" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Non-inferiority of 2 Doses IPV IM vs 3 Doses IPV IM</title>
        <description>To determine if the seroconversion rate of a 2-dose IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
        <time_frame>To be assessed 4 weeks after the last dose</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>3 doses IPV IM at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>2 doses IPV IM at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Non-inferiority of 2 Doses IPV IM vs 3 Doses IPV IM</title>
          <description>To determine if the seroconversion rate of a 2-dose IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
          <population>Per Protocol Population</population>
          <units>percentage of seroconversion</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                    <measurement group_id="O2" value="98.1" lower_limit="94.6" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                    <measurement group_id="O2" value="98.7" lower_limit="95.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Non-inferiority of 2 Doses f-IPV ID vs 3 Doses f-IPV ID</title>
        <description>To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose f-IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
        <time_frame>To be assessed 4 weeks after the last dose</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group C</title>
            <description>3 doses f-IPV ID at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
          <group group_id="O2">
            <title>Group D</title>
            <description>2 doses f-IPV ID at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Non-inferiority of 2 Doses f-IPV ID vs 3 Doses f-IPV ID</title>
          <description>To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose f-IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
          <population>Per Protocol Population</population>
          <units>percentage of seroconversion</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="95.6" upper_limit="98.8"/>
                    <measurement group_id="O2" value="95.9" lower_limit="92.1" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.7" upper_limit="100"/>
                    <measurement group_id="O2" value="97.9" lower_limit="94.8" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Superiority of 2 Doses IPV IM at Different Schedules</title>
        <description>To determine if the seroconversion rate of a 2-dose IPV regimen administered at 14 and 36 weeks of age is superior to that of a 2-dose IPV regimen administered at 10 and 14 weeks of age for poliovirus serotypes 1 and 2.</description>
        <time_frame>To be assessed 4 weeks after the second dose</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>3 doses IPV IM at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>2 doses IPV IM at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Superiority of 2 Doses IPV IM at Different Schedules</title>
          <description>To determine if the seroconversion rate of a 2-dose IPV regimen administered at 14 and 36 weeks of age is superior to that of a 2-dose IPV regimen administered at 10 and 14 weeks of age for poliovirus serotypes 1 and 2.</description>
          <population>Per Protocol Population</population>
          <units>percentage of seroconversion</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" lower_limit="94.6" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.1" lower_limit="94.6" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="83.4" upper_limit="93.1"/>
                    <measurement group_id="O2" value="98.7" lower_limit="95.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Superiority of 2 Dose f-IPV ID at Different Schedules</title>
        <description>To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is superior to that of a 2-dose f-IPV regimen administered at 10 and 14 weeks of age for poliovirus serotypes 1 and 2.</description>
        <time_frame>To be assessed 4 weeks after the second dose</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group C</title>
            <description>3 doses f-IPV ID at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
          <group group_id="O2">
            <title>Group D</title>
            <description>2 doses f-IPV ID at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Superiority of 2 Dose f-IPV ID at Different Schedules</title>
          <description>To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is superior to that of a 2-dose f-IPV regimen administered at 10 and 14 weeks of age for poliovirus serotypes 1 and 2.</description>
          <population>Per Protocol Population</population>
          <units>percentage of seroconversion</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.2" lower_limit="76.5" upper_limit="88.6"/>
                    <measurement group_id="O2" value="95.9" lower_limit="92.1" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9" lower_limit="77.2" upper_limit="89.2"/>
                    <measurement group_id="O2" value="97.9" lower_limit="94.8" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Non-inferiority of 2 Dose f-IPV ID vs 3 Dose IPV IM</title>
        <description>To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
        <time_frame>To be assessed 4 weeks after the last dose</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>3 doses IPV IM at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
          <group group_id="O2">
            <title>Group D</title>
            <description>2 doses f-IPV ID at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Non-inferiority of 2 Dose f-IPV ID vs 3 Dose IPV IM</title>
          <description>To determine if the seroconversion rate of a 2-dose f-IPV regimen administered at 14 and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
          <population>Per Protocol Population</population>
          <units>percentage of seroconversion</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                    <measurement group_id="O2" value="95.9" lower_limit="92.1" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                    <measurement group_id="O2" value="97.9" lower_limit="94.8" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Non Inferiority of 3 Doses f-IPV ID vs 3 Doses IPV IM</title>
        <description>To determine if the seroconversion rate of a 3-dose f-IPV regimen administered at 10, 14, and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen also administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
        <time_frame>To be assessed 4 weeks after the last dose</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>3 doses IPV IM at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
          <group group_id="O2">
            <title>Group C</title>
            <description>3 doses f-IPV ID at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Non Inferiority of 3 Doses f-IPV ID vs 3 Doses IPV IM</title>
          <description>To determine if the seroconversion rate of a 3-dose f-IPV regimen administered at 10, 14, and 36 weeks of age is non-inferior to that of a 3-dose IPV regimen also administered at 10, 14, and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
          <population>Per Protocol Population</population>
          <units>percentage of seroconversion</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                    <measurement group_id="O2" value="98.8" lower_limit="95.6" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.9" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="97.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Non Inferiority of 3 Doses f-IPV ID vs 2 Doses IPV IM</title>
        <description>To determine if the seroconversion rate to a 3-dose regimen of f-IPV administered at 10, 14, and 36 weeks of age is non-inferior to that of a 2-dose IPV regimen administered at 14 and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
        <time_frame>To be assessed 4 weeks after the last dose</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group B</title>
            <description>2 doses IPV IM at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
          <group group_id="O2">
            <title>Group C</title>
            <description>3 doses f-IPV ID at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Non Inferiority of 3 Doses f-IPV ID vs 2 Doses IPV IM</title>
          <description>To determine if the seroconversion rate to a 3-dose regimen of f-IPV administered at 10, 14, and 36 weeks of age is non-inferior to that of a 2-dose IPV regimen administered at 14 and 36 weeks of age for poliovirus serotypes 1 and 2.</description>
          <population>Per Protocol Population</population>
          <units>percentage of seroconversion</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="94.6" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.8" lower_limit="95.6" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="95.5" upper_limit="99.8"/>
                    <measurement group_id="O2" value="100" lower_limit="97.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing SAEs, IMEs and/or Severe Local Reactions</title>
        <description>To assess the safety of each vaccine (IPV and f-IPV) as measured by the number of subjects experiencing serious adverse events (SAEs), important medical events (IMEs) and/or severe local reactions.</description>
        <time_frame>To be assessed throughout the complete study period, approx. 13 months</time_frame>
        <population>Total Vaccinated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>3 doses IPV IM at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>2 doses IPV IM at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>3 doses f-IPV ID at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
          <group group_id="O4">
            <title>Group D</title>
            <description>2 doses f-IPV ID at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing SAEs, IMEs and/or Severe Local Reactions</title>
          <description>To assess the safety of each vaccine (IPV and f-IPV) as measured by the number of subjects experiencing serious adverse events (SAEs), important medical events (IMEs) and/or severe local reactions.</description>
          <population>Total Vaccinated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="170"/>
                <count group_id="O4" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IME</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SLR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>13 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>3 doses IPV IM at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>2 doses IPV IM at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
        </group>
        <group group_id="E3">
          <title>Group C</title>
          <description>3 doses f-IPV ID at 10, 14 &amp; 36 weeks of age incl. blood sampling at 10, 14, 18 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
        </group>
        <group group_id="E4">
          <title>Group D</title>
          <description>2 doses f-IPV ID at 14 &amp; 36 weeks of age incl. blood sampling at 14, 18, 36 &amp; 40 weeks.&#xD;
f-IPV: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenogenital syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Glucose-6-Phosphate Dehydrogenase Deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="172"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cow milk intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cow milk intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ricardo R√ºttimann</name_or_title>
      <organization>FIDEC Corporationa</organization>
      <phone>+17863546335</phone>
      <email>rruttimann@fidec-online.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

